Toggle light / dark theme

Taking advantage of powerful advances in CRISPR gene editing, scientists at the University of California San Diego have set their sights on one of society’s most formidable threats to human health.

A research team led by Andrés Valderrama at UC San Diego School of Medicine and Surashree Kulkarni of the Division of Biological Sciences has developed a new CRISPR-based gene-drive system that dramatically increases the efficiency of inactivating a gene rendering bacteria antibiotic-resistant. The new system leverages technology developed by UC San Diego biologists in insects and mammals that biases genetic inheritance of preferred traits called “active genetics.” The new “pro-active” genetic system, or Pro-AG, is detailed in a paper published December 16 in Nature Communications.

Widespread prescriptions of and use in animal food production have led to a rising prevalence of antimicrobial resistance in the environment. Evidence indicates that these environmental sources of antibiotic resistance are transmitted to humans and contribute to the current health crisis associated with the dramatic rise in drug-resistant microbes. Health experts predict that threats from antibiotic resistance could drastically increase in the coming decades, leading to some 10 million drug-resistant disease deaths per year by 2050 if left unchecked.

The first driverless cars were supposed to be deployed on the roads of American cities in 2019, but just a few days before the end of the year, the lofty promises of car manufacturers and Silicon Valley remain far from becoming reality.

Recent accidents, such as those involving Tesla cars equipped with Autopilot, a driver assistance software, have shown that “the technology is not ready,” said Dan Albert, critic and author of the book “Are We There Yet?” on the history of the American automobile.

He questioned the optimistic sales pitch that autonomous cars would help reduce road deaths — 40,000 every year in the United States, mostly due to human error — because these vehicles themselves have caused deaths.

Liz Parrish in Spanish is still good… AEWR.


Briefing of the highlights of second day (Nov 15, 2019) at the Longevity World Forum that took place in Valencia, Spain.

Liz Parrish, founder and CEO of BioViva Science, took the stage that day and was closely followed by the media press covering the event.

We will have a New Presentation on Age Reversal and Cryonics by Bill Faloon. 🤩 😎

Come early and enjoy snacks and conversation and stay afterward as we have a delicious 5-star dinner reception for Bill Faloon.

Before and after the service we will enjoy tasty food and interesting discussions on Age Reversal, Cryonics, Singularity and other topics of interest for all Immortalists.

The National Institutes of Health (NIH) estimates that in 2018, over 10 million teens and adults misused opioids. The prescription of opioids to treat patient pain is one of many factors contributing to this epidemic; to solve it, a multipronged approach is needed.

Two new Mayo Clinic studies — one in clinical practice and one in the laboratory — could offer new solutions to help patients manage pain without the use of opioids. These projects have been singled out for federal funding under the NIH’s Helping to End Addiction Long-Term (HEAL) Initiative, a multimillion dollar, multiorganizational approach to providing pain-treatment alternatives and turning the tide on the opioid crisis.

“Opioids remain one part of the continuum of pain treatment,” says Andrea Cheville, M.D., a rehabilitation physician at Mayo and member of the National Academy of Medicine. “There are other options that work as well, or better in some cases, with fewer risks. Our new research mirrors a broad Mayo priority — finding the safest, most effective way to help our patients manage acute or chronic pain.”